Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell LymphomaFrederick L. Locke, Jason R. Westin, David B. Miklos et al.|New England Journal of Medicine|2021Cited by 1.6k
Survival with Axicabtagene Ciloleucel in Large B-Cell LymphomaJason R. Westin, Frederick L. Locke, Olalekan O. Oluwole et al.|New England Journal of Medicine|2023Cited by 437
Impact of tumor microenvironment on efficacy of anti-CD19 CAR T cell therapy or chemotherapy and transplant in large B cell lymphomaFrederick L. Locke, Jérôme Galon, Pier Luigi Zinzani et al.|Nature Medicine|2024Cited by 114
Tumor gene expression signatures associated with outcome in large B−cell lymphoma treated with CD19-directed CAR T−cell therapy (axicabtagene ciloleucel)Yuan Tian, Simone Filosto, Justin A. Budka et al.|Frontiers in Oncology|2025Cited by 2